Verisante Technology has secured Australian approval for its Verisante Aura, an innovative, non-invasive medical device for the early detection of skin cancer.

Aura is a non-invasive optical system used to identify suspected skin lesions for diagnosis as either skin cancer or a benign disorder within two seconds.

The optical system uses Raman spectroscopy to automate the current process of diagnosis, allowing for the rapid scanning of the 20 to 40 skin lesions on at-risk individuals, improving patient outcomes and comfort.

Verisante Technology president and CEO Thomas Braun said after Canadian and European approval earlier this quarter, obtaining Australian approval completes the company’s regulatory goals for 2011.